David Gandara

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Wakelee Heather; Loo Bill W; Kernstine Kemp H; Putnam Joe Bill; Edelman Martin J; Vokes Everett E; Schiller Joan H; Baas Paul; Saijo Nagahiro; Adjei Alex; Goss Glenwood; Choy Hak; Gandara David R
Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress.
Gandara David R; Mack Philip C; Li Tianhong; Lara Primo N; Herbst Roy S
Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012.
Shibata Stephen I; Doroshow James H; Frankel Paul; Synold Timothy W; Yen Yun; Gandara David R; Lenz Heinz-Josef; Chow Warren A; Leong Lucille A; Lim Dean; Margolin Kim A; Morgan Robert J; Somlo George; Newman Edward M
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of David Gandara (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Wakelee Heather; Loo Bill W; Kernstine Kemp H; Putnam Joe Bill; Edelman Martin J; Vokes Everett E; Schiller Joan H; Baas Paul; Saijo Nagahiro; Adjei Alex; Goss Glenwood; Choy Hak; Gandara David R
Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress.
Clinical lung cancer 2009;10(6):395-404.
2009: Gandara David R; Mack Philip C; Li Tianhong; Lara Primo N; Herbst Roy S
Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking toward 2012.
Clinical lung cancer 2009;10(6):392-4.
2009: Shibata Stephen I; Doroshow James H; Frankel Paul; Synold Timothy W; Yen Yun; Gandara David R; Lenz Heinz-Josef; Chow Warren A; Leong Lucille A; Lim Dean; Margolin Kim A; Morgan Robert J; Somlo George; Newman Edward M
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
Cancer chemotherapy and pharmacology 2009;64(6):1149-55.
2009: Sangha Randeep; Lara Primo N; Adjei Alex A; Baas Paul; Choy Hak; Gaspar Laurie E; Goss Glenwood; Saijo Nagahiro; Schiller Joan H; Vokes Everett E; Gandara David R
Cooperative group research endeavors in small-cell lung cancer: current and future directions.
Clinical lung cancer 2009;10(5):322-30.
2009: Ramanathan Ramesh K; Belani Chandra P; Singh Deepti A; Tanaka Michael; Lenz Heinz-Josef; Yen Yun; Kindler Hedy L; Iqbal Syma; Longmate Jeff; Mack Philip C; Lurje Georg; Gandour-Edwards Regina; Dancey Janet; Gandara David R
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.
Cancer chemotherapy and pharmacology 2009;64(4):777-83.
2009: Albain Kathy S; Swann R Suzanne; Rusch Valerie W; Turrisi Andrew T; Shepherd Frances A; Smith Colum; Chen Yuhchyau; Livingston Robert B; Feins Richard H; Gandara David R; Fry Willard A; Darling Gail; Johnson David H; Green Mark R; Miller Robert C; Ley Joanne; Sause Willliam T; Cox James D
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.
Lancet 2009;374(9687):379-86.
2009: Gandara David R; Simons Jasper
A decade of clinical lung cancer.
Clinical lung cancer 2009;10(4):216.
2009: Davies Angela M; Ho Cheryl; Beckett Laurel; Lau Derick; Scudder Sidney A; Lara Primo N; Perkins Natasha; Gandara David R
Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(7):862-8.
2009: Gandara David R; Kawaguchi Tomoya; Crowley John; Moon James; Furuse Kiyoyuki; Kawahara Masaaki; Teramukai Satoshi; Ohe Yuichiro; Kubota Kaoru; Williamson Stephen K; Gautschi Oliver; Lenz Heinz Josef; McLeod Howard L; Lara Primo N; Coltman Charles Arthur; Fukuoka Masahiro; Saijo Nagahiro; Fukushima Masanori; Mack Philip C
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(21):3540-6.
2009: Le Quynh-Thu X; Moon James; Redman Mary; Williamson Stephen K; Lara Primo N; Goldberg Zelanna; Gaspar Laurie E; Crowley John J; Moore Dennis F; Gandara David R
Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(18):3014-9.
2009: Gandara David R; Lara Primo N; Mack Philip; Scagliotti Giorgio
Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making.
Clinical lung cancer 2009;10(3):148-50.
2009: Lara Primo N; Natale Ronald; Crowley John; Lenz Heinz Josef; Redman Mary W; Carleton Jane E; Jett James; Langer Corey J; Kuebler J Philip; Dakhil Shaker R; Chansky Kari; Gandara David R
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(15):2530-5.
2009: Chew Helen K; Doroshow James H; Frankel Paul; Margolin Kim A; Somlo George; Lenz Heinz-Josef; Gordon Michael; Zhang Wu; Yang Dongyun; Russell Christy; Spicer Darcy; Synold Tim; Bayer Robert; Hantel Alexander; Stiff Patrick J; Tetef Merry L; Gandara David R; Albain Kathy S
Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(13):2163-9.
2009: Purnell Phillip R; Mack Philip C; Tepper Clifford G; Evans Christopher P; Green Tim P; Gumerlock Paul H; Lara Primo N; Gandara David R; Kung Hsing-Jien; Gautschi Oliver
The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(4):448-54.
2009: Sangha Randeep; Lara Primo N; Mack Philip C; Gandara David R
Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
Current opinion in oncology 2009;21(2):116-23.
2009: Lara Primo N; Longmate Jeff; Evans Christopher P; Quinn David I; Twardowski Przemyslaw; Chatta Gurkamal; Posadas Edwin; Stadler Walter; Gandara David R
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
Anti-cancer drugs 2009;20(3):179-84.
2009: Chen Gigi; Huynh Minh; Fehrenbacher Lou; West Howard; Lara Primo N; Yavorkovsky Leonid L; Russin Michael; Goldstein Desiree; Gandara David; Lau Derick
Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(9):1401-4.
2009: Cheung Eric; Pinski Jacek; Dorff Tanya; Groshen Susan; Quinn David I; Reynolds C Patrick; Maurer Barry J; Lara Primo N; Tsao-Wei Denice D; Twardowski Przemyslaw; Chatta Gurkamal; McNamara Mark; Gandara David R
Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial.
Clinical genitourinary cancer 2009;7(1):43-50.
2009: Ramalingam Suresh S; Belani Chandra P; Ruel Christopher; Frankel Paul; Gitlitz Barbara; Koczywas Marianna; Espinoza-Delgado Igor; Gandara David
Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(1):97-101.
2009: Davies Angela M; Chansky Kari; Lara Primo N; Gumerlock Paul H; Crowley John; Albain Kathy S; Vogel Stanley J; Gandara David R;
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(1):87-92.
2008: Wakelee Heather; Kernstine Kemp; Vokes Everett; Schiller Joan; Baas Paul; Saijo Nagahiro; Adjei Alex; Goss Glenwood; Gaspar Laurie; Gandara David R; Choy Hak; Putnam Joe Bill
Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer.
Clinical lung cancer 2008;9(6):346-51.
2008: Schultheis Anne M; Lurje Georg; Rhodes Katrin E; Zhang Wu; Yang Dongyun; Garcia Agustin A; Morgan Robert; Gandara David; Scudder Sidney; Oza Amit; Hirte Hal; Fleming Gini; Roman Lynda; Lenz Heinz-Josef
Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(22):7554-63.
2008: Luu Thehang H; Morgan Robert J; Leong Lucille; Lim Dean; McNamara Mark; Portnow Jana; Frankel Paul; Smith David D; Doroshow James H; Wong Carol; Aparicio Ana; Gandara David R; Somlo George
A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(21):7138-42.
2008: Mack Philip C; Redman Mary W; Chansky Kari; Williamson Stephen K; Farneth Nichole C; Lara Primo N; Franklin Wilbur A; Le Quynh-Thu; Crowley John J; Gandara David R;
Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(29):4771-6.
2008: Gandara David R; Lara Primo N; Natale Ronald; Belani Chandra
Progress in small-cell lung cancer: the lowest common denominator.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(26):4236-8.
2008: Raz Dan J; Ray M Roshni; Kim Jae Y; He Biao; Taron Miquel; Skrzypski Marcin; Segal Mark; Gandara David R; Rosell Rafael; Jablons David M
A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(17):5565-70.
2008: Hesketh Paul J; Chansky Kari; Wozniak Antoinette J; Hirsch Fred R; Spreafico Anna; Moon James; Mack Philip C; Marchello Benjamin T; Franklin Wilbur A; Crowley John J; Gandara David R
Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(9):1026-31.
2008: Yen Y; Lim Dean W; Chung Vincent; Morgan Robert J; Leong Lucille A; Shibata Stephen I; Wagman Lawrence D; Marx Howard; Chu Peiguo G; Longmate Jeffrey A; Lenz Heinz-Josef; Ramanathan Ramesh K; Belani Chandra P; Gandara David R
Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial.
American journal of clinical oncology 2008;31(4):317-22.
2008: Chee Karen G; Nguyen Danh V; Brown Monica; Gandara David R; Wun Ted; Lara Primo N
Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited.
Archives of internal medicine 2008;168(14):1541-9.
2008: Hirsch Fred R; Herbst Roy S; Olsen Christine; Chansky Kari; Crowley John; Kelly Karen; Franklin Wilbur A; Bunn Paul A; Varella-Garcia Marileila; Gandara David R
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(20):3351-7.
2008: Scagliotti Giorgio Vittorio; Parikh Purvish; von Pawel Joachim; Biesma Bonne; Vansteenkiste Johan; Manegold Christian; Serwatowski Piotr; Gatzemeier Ulrich; Digumarti Raghunadharao; Zukin Mauro; Lee Jin S; Mellemgaard Anders; Park Keunchil; Patil Shehkar; Rolski Janusz; Goksel Tuncay; de Marinis Filippo; Simms Lorinda; Sugarman Katherine P; Gandara David
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(21):3543-51.
2008: Lau Derick; Johl Jewel; Huynh Minh; Davies Angela; Tanaka Michael; Lara Primo; Gandara David
Population-based phase I trial of irinotecan and epirubicin.
American journal of clinical oncology 2008;31(3):226-30.
2008: Hirsch Fred R; Dziadziuszko Rafal; Varella-Garcia Marileila; Franklin Wilbur A; Gandara David R; Bunn Paul A
First-generation epidermal growth factor receptor inhibitors in non-small cell lung cancer: clinical impact of the epidermal growth factor receptor fluorescence in situ hybridization assay.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(6 Suppl 2):S138-42.
2008: Xiao Gary Guishan; Zhou Bing-Sen; Somlo George; Portnow Jana; Juhasz Agnes; Un Frank; Chew Helen; Gandara David; Yen Yun
Identification of F-box/LLR-repeated protein 17 as potential useful biomarker for breast cancer therapy.
Cancer genomics & proteomics 2008;5(3-4):151-60.
2008: Einhorn Lawrence H; Bonomi Philip; Bunn Paul A; Camidge D Ross; Carbone David Paul; Choy Hak; Dubinett Steven M; Gandara David R; Gaspar Laurie E; Govindan Ramaswamy; Johnson David H; Minna John D; Scagliotti Giorgio; West Howard J; Herbst Roy S
Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(5):545-55.
2008: Kelly Karen; Chansky Kari; Gaspar Laurie E; Albain Kathy S; Jett James; Ung Yee C; Lau Derick H M; Crowley John J; Gandara David R
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(15):2450-6.
2008: Calhoun Royce; Jablons David; Lau Derick; Gandara David R
Adjuvant treatment of stage IB NSCLC: the problem of stage subset heterogeneity.
Oncology (Williston Park, N.Y.) 2008;22(5):511-6; discussion 516, 521-3.
2008: Gautschi Oliver; Tepper Clifford G; Purnell Phillip R; Izumiya Yoshihiro; Evans Christopher P; Green Tim P; Desprez Pierre Y; Lara Primo N; Gandara David R; Mack Philip C; Kung Hsing-Jien
Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer.
Cancer research 2008;68(7):2250-8.
2008: Langer Corey J; Wakelee Heather; Schiller Joan; Choy Hak; Shepherd Frances; Vokes Everett E; Adjei Alex A; Baas Paul; Saijo Nagahiro; Gandara David R
Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?
Clinical lung cancer 2008;9(2):85-91.
2008: Gautschi Oliver; Heighway Jim; Mack Philip C; Purnell Phillip R; Lara Primo N; Gandara David R
Aurora kinases as anticancer drug targets.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(6):1639-48.
2008: Chen Gigi; Huynh Minh; Chen Allan; Fehrenbacher Lou; Gandara David; Lau Derick
Chemotherapy for brain metastases in small-cell lung cancer.
Clinical lung cancer 2008;9(1):35-8.
2008: Wakelee Heather; Langer Corey; Vokes Everett; Schiller Joan; Baas Paul; Saijo Nagahiro; Adjei Alex; Shepherd Frances; Choy Hak; Gandara David R
Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer.
Clinical lung cancer 2008;9(1):9-15.
2008: Lara Primo N; Redman Mary W; Kelly Karen; Edelman Martin J; Williamson Stephen K; Crowley John J; Gandara David R;
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(3):463-7.
2008: Davies Angela M; Ruel Christopher; Lara Primo N; Lau Derick H; Gumerlock Paul H; Bold Richard; Shibata Stephen; Lenz Heinz-Josef; Schenkein David P; Gandara David R
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(1):68-74.
2008: Garcia Agustin A; Hirte Hal; Fleming Gini; Yang Dongyun; Tsao-Wei Denice D; Roman Lynda; Groshen Susan; Swenson Steve; Markland Frank; Gandara David; Scudder Sidney; Morgan Robert; Chen Helen; Lenz Heinz-Josef; Oza Amit M
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(1):76-82.
2008: Umutyan Ari; Chiechi Christine; Beckett Laurel A; Paterniti Debora A; Turrell Corinne; Gandara David R; Davis Sharon W; Wun Ted; Chen Moon S; Lara Primo N
Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign.
Cancer 2008;112(1):212-9.
2008: Sangha Randeep; Lara Primo N; Mack Philip; Gandara David R
Targeted therapies in non-small-cell lung cancer: a paradigm in evolution.
Clinical lung cancer 2008;9 Suppl 3():S90-1.
2008: Gautschi Oliver; Mack Philip C; Davies Angela M; Jablons David M; Rosell Rafael; Gandara David R
Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions.
Clinical lung cancer 2008;9 Suppl 3():S129-38.
2007: Chee Karen G; Longmate Jeff; Quinn David I; Chatta Gurkamal; Pinski Jacek; Twardowski Przemyslaw; Pan Chong-Xian; Cambio Angelo; Evans Christopher P; Gandara David R; Lara Primo N
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.
Clinical genitourinary cancer 2007;5(7):433-7.
2007: Davies Angela M; Ho Cheryl; Metzger Alex S; Beckett Laurel A; Christensen Scott; Tanaka Michael; Lara Primo N; Lau Derick H; Gandara David R
Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(12):1112-6.
2007: Mahaffey Christopher M; Davies Angela M; Lara Primo N; Pryde Brandi; Holland William; Mack Philip C; Gumerlock Paul H; Gandara David R
Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation.
Clinical lung cancer 2007;8(9):548-53.
2007: Gandara David R; Sangha Randeep; Davies Angela M
Bevacizumab: optimal dose, schedule, and duration of therapy.
Clinical lung cancer 2007;8(9):522-3.
2007: Margolin Kim; Synold Timothy W; Lara Primo; Frankel Paul; Lacey Simon F; Quinn David I; Baratta Tracey; Dutcher Janice P; Xi Bixin; Diamond Don J; Gandara David R
Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium.
Journal of cancer research and clinical oncology 2007;133(10):705-11.
2007: Gautschi O; Huegli B; Ziegler A; Gugger M; Heighway J; Ratschiller D; Mack P C; Gumerlock P H; Kung H J; Stahel R A; Gandara D R; Betticher D C
Origin and prognostic value of circulating KRAS mutations in lung cancer patients.
Cancer letters 2007;254(2):265-73.
2007: Davies Angela M; Lara Primo N; Mack Philip C; Gandara David R
Incorporating bortezomib into the treatment of lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 2):s4647-51.
2007: Davies Angela M; Ho Cheryl; Hesketh Paul J; Beckett Laurel A; Lara Primo N; Lau Derick H M; Gandara David R
Erlotinib and vinorelbine in advanced malignant solid tumors: a phase I study.
Investigational new drugs 2007;25(4):351-5.
2007: Ho Cheryl; Davies Angela; Mack Philip; Gandara David
Dual inhibition: combining epidermal growth factor-targeted therapies in non-small-cell lung cancer.
Clinical lung cancer 2007;8(7):420-4.
2007: Gandara David R; Wakelee Heather; Calhoun Royce; Jablons David
Adjuvant chemotherapy of stage I non-small cell lung cancer in North America.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(7 Suppl 3):S125-7.
2007: Cobo Manuel; Isla Dolores; Massuti Bartomeu; Montes Ana; Sanchez Jose Miguel; Provencio Mariano; Viñolas Nuria; Paz-Ares Luis; Lopez-Vivanco Guillermo; Muñoz Miguel Angel; Felip Enriqueta; Alberola Vicente; Camps Carlos; Domine Manuel; Sanchez Jose Javier; Sanchez-Ronco Maria; Danenberg Kathleen; Taron Miquel; Gandara David; Rosell Rafael
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(19):2747-54.
2007: Raz Dan J; Zell Jason A; Ou S-H Ignatius; Gandara David R; Anton-Culver Hoda; Jablons David M
Natural history of stage I non-small cell lung cancer: implications for early detection.
Chest 2007;132(1):193-9.
2007: Synold Timothy W; Takimoto Chris H; Doroshow James H; Gandara David; Mani Sridhar; Remick Scot C; Mulkerin Daniel L; Hamilton Anne; Sharma Sunil; Ramanathan Ramesh K; Lenz Heinz Josef; Graham Martin; Longmate Jeffrey; Kaufman Bennett M; Ivy Percy;
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(12):3660-6.
2007: Garland Linda L; Rankin Cathryn; Gandara David R; Rivkin Saul E; Scott Katherine M; Nagle Raymond B; Klein-Szanto Andres J P; Testa Joseph R; Altomare Deborah A; Borden Ernest C
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(17):2406-13.
2007: Yoneda Ken Y; Shelton David K; Beckett Laurel A; Gandara David R
Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(6):537-43.
2007: Akerley Wallace; McCoy Jason; Hesketh Paul J; Goodwin J Wendall; Bearden James D; Atkins James N; Chansky Kari; Crowley John J; Gandara David R;
Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(6):526-30.
2007: Hesketh Paul J; Lilenbaum Rogerio C; Chansky Kari; Dowlati Afshin; Graham Patricia; Chapman Robert A; Crowley John J; Gandara David R
Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(6):494-8.
2007: Hesketh Paul J; Chansky Kari; Israel Valerie; Grapski Richard T; Mekhail Tarek M; Spiridonidis C Harris; Mills Glenn M; Kelly Karen; Crowley John J; Gandara David R
Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(5):440-4.
2007: Samlowski Wolfram E; Moon James; Kuebler J Philip; Nichols Craig R; Gandara David R; Ozer Howard; Williamson Stephen K; Atkins James N; Schuller David E; Ensley John F
Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study.
Cancer investigation 2007;25(3):182-8.
2007: Hirsch F R; Varella-Garcia M; Cappuzzo F; McCoy J; Bemis L; Xavier A C; Dziadziuszko R; Gumerlock P; Chansky K; West H; Gazdar A F; Crino L; Gandara D R; Franklin W A; Bunn P A
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(4):752-60.
2007: Wakelee Heather; Dubey Sarita; Gandara David
Optimal adjuvant therapy for non-small cell lung cancer--how to handle stage I disease.
The oncologist 2007;12(3):331-7.
2007: Morgan R J; Synold T W; Gandara D; Muggia F; Scudder S; Reed E; Margolin K; Raschko J; Leong L; Shibata S; Tetef M; Vasilev S; McGonigle K; Longmate J; Yen Y; Chow W; Somlo G; Carroll M; Doroshow J H
Phase II trial of carboplatin and infusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2007;17(2):373-8.
2007: Shibata Stephen; Chow Warren; Frankel Paul; Juhasz Agnes; Leong Lucille; Lim Dean; Margolin Kim; Morgan Robert; Newman Edward; Somlo George; Yen Yun; Synold Timothy; Gandara David; Lenz Heinz-Josef; Doroshow James
A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression.
Cancer chemotherapy and pharmacology 2007;59(4):549-57.
2007: Wang Henry; Ryu Janice; Gandara David; Bold Richard J; Urayama Shiro; Tanaka Michael; Goldberg Zelanna; Follette David; Narayan Samir; Lau Derick
A phase II study of paclitaxel, carboplatin, and radiation with or without surgery for esophageal cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2007;2(2):153-7.
2007: Gandara David R; Davies Angela M; Gautschi Oliver; Mack Philip C; Lau Derick H; Lara Primo N; Hirsch Fred R
Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies.
Clinical lung cancer 2007;8 Suppl 2():S61-7.
2007: Rusch Valerie W; Giroux Dorothy J; Kraut Michael J; Crowley John; Hazuka Mark; Winton Timothy; Johnson David H; Shulman Lawrence; Shepherd Frances; Deschamps Claude; Livingston Robert B; Gandara David
Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(3):313-8.
2006: Yoneda Ken Y; Hardin Kimberly A; Gandara David R; Shelton David K
Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma.
Clinical lung cancer 2006;8 Suppl 1():S31-5.
2006: Gandara David R; Aberle Denise; Lau Derick; Jett James; Akhurst Tim; Heelan Robert; Mulshine James; Berg Christine; Patz Edward F
Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(9 Suppl):S20-6.
2006: Lara Primo N; Chansky Kari; Davies Angela M; Franklin Wilbur A; Gumerlock Paul H; Guaglianone Perry P; Atkins James N; Farneth Nichole; Mack Philip C; Crowley John J; Gandara David R
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(9):996-1001.
2006: Hesketh Paul J; McCoy Jason; Dunphy Frank R; Bearden James D; Weiss Geoffrey R; Giguere Jeffrey K; Atkins James N; Dakhil Shaker R; Kelly Karen; Crowley John J; Gandara David R
Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(9):991-5.
2006: Davies Angela M; Chansky Kari; Lau Derick H M; Leigh Bryan R; Gaspar Laurie E; Weiss Geoffrey R; Wozniak Antoinette J; Crowley John J; Gandara David R;
Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(33):5242-6.
2006: Gandara David R; Chansky Kari; Albain Kathy S; Gaspar Laurie E; Lara Primo N; Kelly Karen; Crowley John; Livingston Robert
Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504).
Clinical lung cancer 2006;8(2):116-21.
2006: Gautschi Oliver; Mack Philip C; Davies Angela M; Lara Primo N; Gandara David R
Aurora kinase inhibitors: a new class of targeted drugs in cancer.
Clinical lung cancer 2006;8(2):93-8.
2006: Hesketh Paul J; Chansky Kari; Lau Derick H M; Doroshow James H; Moinpour Carol M; Chapman Robert A; Goodwin J Wendall; Gross Howard M; Crowley John J; Gandara David R
Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(6):537-44.
2006: Wakelee Heather A; Schiller Joan H; Gandara David R
Current status of adjuvant chemotherapy for stage IB non-small-cell lung cancer: implications for the New Intergroup Trial.
Clinical lung cancer 2006;8(1):18-21.
2006: Gandara David R; Davies Angela M
Oral second-line chemotherapy for advanced non-small-cell lung cancer: the bottom line.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(18):2700-1.
2006: Davies Angela M; Ho Cheryl; Lara Primo N; Mack Philip; Gumerlock Paul H; Gandara David R
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.
Clinical lung cancer 2006;7(6):385-8.
2006: Ho Cheryl; Davies Angela M; Lara Primo N; Gandara David R
Second-line treatment for advanced-stage non-small-cell lung cancer: current and future options.
Clinical lung cancer 2006;7 Suppl 4():S118-25.
2006: Juhasz Agnes; Vassilakos Aikaterini; Chew Helen K; Gandara David; Yen Yun
Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment.
Oncology reports 2006;15(5):1299-304.
2006: West Howard L; Franklin Wilbur A; McCoy Jason; Gumerlock Paul H; Vance Ralph; Lau Derick H M; Chansky Kari; Crowley John J; Gandara David R
Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(12):1807-13.
2006: Williamson Stephen K; McCoy Sheryl A; Gandara David R; Dakhil Shaker R; Yost Kathleen J; Paradelo Jorge C; Atkins James N; Blanke Charles D; Abbruzzese James L;
Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.
American journal of clinical oncology 2006;29(2):116-22.
2006: Lara Primo N; Gandara David R; Natale Ronald B
Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.
Clinical lung cancer 2006;7(5):353-6.
2006: Gandara David R
Bronchioloalveolar carcinoma: the "changing face of lung cancer".
Clinical lung cancer 2006;7(5):299.
2006: Paz-Ares Luis; Douillard Jean-Yves; Koralewski Piotr; Manegold Christian; Smit Egbert F; Reyes José Miguel; Chang Gee-Chen; John William J; Peterson Patrick M; Obasaju Coleman K; Lahn Michael; Gandara David R
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(9):1428-34.
2006: Lara Primo N; Stadler Walter M; Longmate Jeff; Quinn David I; Wexler Jason; Van Loan Marta; Twardowski Przemyslaw; Gumerlock Paul H; Vogelzang Nicholas J; Vokes Everett E; Lenz Heinz Josef; Doroshow James H; Gandara David R
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(5):1556-63.
2006: Lara Primo N; Koczywas Mariana; Quinn David I; Lenz Heinz Josef; Davies Angela M; Lau Derick H M; Gumerlock Paul H; Longmate Jeff; Doroshow James H; Schenkein David; Kashala Oscar; Gandara David R
Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(2):126-34.
2006: Unger Joseph M; Coltman Charles A; Crowley John J; Hutchins Laura F; Martino Silvana; Livingston Robert B; Macdonald John S; Blanke Charles D; Gandara David R; Crawford E David; Albain Kathy S
Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(1):141-4.
2005: Gandara David R; Vallières Eric; Gaspar Laurie E; Kelly Karen; Albain Kathy S; Herbst Roy S; Lara Primo N; Mack Philip; Gumerlock Paul H; Crowley John J
Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy.
Clinical lung cancer 2005;7 Suppl 3():S93-7.
2005: Lara Primo N; Paterniti Debora A; Chiechi Christine; Turrell Corinne; Morain Claudia; Horan Nora; Montell Lisa; Gonzalez Jose; Davis Sharon; Umutyan Ari; Martel Cynthia L; Gandara David R; Wun Ted; Beckett Laurel A; Chen Moon S
Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9282-9.
2005: Williamson Stephen K; Crowley John J; Lara Primo N; McCoy Jason; Lau Derick H M; Tucker Robert W; Mills Glenn M; Gandara David R;
Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9097-104.
2005: Gandara David R; Hesketh Paul
Treatment options for patients with advanced-stage non-small-cell lung cancer: who are the "elderly" and who are the "unfit"?
Clinical lung cancer 2005;7(3):154-5.
2005: Lara Primo N; Bold Richard J; Mack Philip C; Davies Angela M; Gumerlock Paul H; Gandara David R
Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.
Clinical lung cancer 2005;7 Suppl 2():S67-71.
2005: Davies Angela M; Lara Primo N; Mack Philip C; Gumerlock Paul H; Bold Richard J; Gandara David R
Bortezomib-based combinations in the treatment of non-small-cell lung cancer.
Clinical lung cancer 2005;7 Suppl 2():S59-63.
2005: Hirsch Fred R; Varella-Garcia Marileila; McCoy Jason; West Howard; Xavier Ana Carolina; Gumerlock Paul; Bunn Paul A; Franklin Wilbur A; Crowley John; Gandara David R;
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):6838-45.
2005: Gandara David R; Gumerlock Paul H
Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):5856-8.
2005: Mortenson Melinda M; Schlieman Michael G; Virudachalam Subbulakshmi; Lara Primo N; Gandara David G; Davies Angela M; Bold Richard J
Reduction in BCL-2 levels by 26S proteasome inhibition with bortezomib is associated with induction of apoptosis in small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2005;49(2):163-70.
2005: Gandara David; Narayan Samir; Lara Primo N; Goldberg Zelanna; Davies Angela; Lau Derrick H M; Mack Philip; Gumerlock Paul; Vijayakumar Srinivasan
Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13 Pt 2):5057s-5062s.
2005: Lynch Thomas J; Bogart Jeffrey A; Curran Walter J; DeCamp Malcolm M; Gandara David R; Goss Glenwood; Henschke Claudia I; Jett James R; Johnson Bruce E; Kelly Karen L; Le Chevalier Thierry; Mulshine James L; Scagliotti Giorgio V; Schiller Joan H; Shaw Alice; Thatcher Nick; Vokes Everett E; Wood Douglas E; Hart Carol
Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13 Pt 2):4981s-4983s.
2005: West H L; Crowley J J; Vance R B; Franklin W A; Livingston R B; Dakhil S R; Giguere J K; Rivkin S E; Kraut M; Chansky K; Gandara D R;
Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(7):1076-80.
2005: Winton Timothy; Livingston Robert; Johnson David; Rigas James; Johnston Michael; Butts Charles; Cormier Yvon; Goss Glenwood; Inculet Richard; Vallieres Eric; Fry Willard; Bethune Drew; Ayoub Joseph; Ding Keyue; Seymour Lesley; Graham Barbara; Tsao Ming-Sound; Gandara David; Kesler Kenneth; Demmy Todd; Shepherd Frances;
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.
The New England journal of medicine 2005;352(25):2589-97.
2005: Lara Primo N; Mack Philip C; Synold Timothy; Frankel Paul; Longmate Jeff; Gumerlock Paul H; Doroshow James H; Gandara David R
The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4444-50.
2005: Gaspar Laurie E; Chansky Kari; Albain Kathy S; Vallieres Eric; Rusch Valerie; Crowley John J; Livingston Robert B; Gandara David R
Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(13):2955-61.
2005: Turrisi Andrew T; Crowley John; Albain Kathy; Gaspar Laurie; Gandara David
Southwest Oncology Group: two decades of experience in non-small cell lung cancer.
Seminars in oncology 2005;32(2 Suppl 3):S119-21.
2005: Lau Derick; Seibert Anthony; Gandara David; Laptalo Luko; Geraghty Este; Coulon Christopher
Computer-assisted image analysis of bronchioloalveolar carcinoma.
Clinical lung cancer 2005;6(5):281-6.
2005: Lara Primo N; Law Lisa Y; Wright John J; Frankel Paul; Twardowski Przemyslaw; Lenz Heinz Josef; Lau Derick H M; Kawaguchi Tomoya; Gumerlock Paul H; Doroshow James H; Gandara David R
Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial.
Anti-cancer drugs 2005;16(3):317-21.
2004: Meyers Frederick J; Linder John; Beckett Laurel; Christensen Scott; Blais Joan; Gandara David R
Simultaneous care: a model approach to the perceived conflict between investigational therapy and palliative care.
Journal of pain and symptom management 2004;28(6):548-56.
2004: Mack Philip C; Jones Angela A; Gustafsson Matthew H; Gandara David R; Gumerlock Paul H; Goldberg Zelanna
Enhancement of radiation cytotoxicity by UCN-01 in non-small cell lung carcinoma cells.
Radiation research 2004;162(6):623-34.
2004: Lau Derick; Guo Linlang; Gandara David; Young Lawrence J T; Xue Ling
Is inhibition of cancer angiogenesis and growth by paclitaxel schedule dependent?
Anti-cancer drugs 2004;15(9):871-5.
2004: Morgan Robert J; Synold Timothy W; Gandara David; Muggia Franco; Scudder Sidney; Reed Eddie; Margolin Kim; Raschko James; Leong Lucille; Shibata Stephen; Tetef Merry; Vasilev Steven; McGonigle Kathryn; Longmate Jeff; Yen Yun; Chow Warren; Somlo George; Carroll Mary; Doroshow James H
Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer.
Cancer chemotherapy and pharmacology 2004;54(4):283-9.
2004: Martel Cynthia L; Li Yueju; Beckett Laurel; Chew Helen; Christensen Scott; Davies Angela; Lam Kit S; Lau Derick H; Meyers Frederick J; O'donnell Robert T; Richman Carol; Scudder Sidney; Tanaka Michael; Tuscano Joseph; Welborn Jeanna; Wun Theodore; Gandara David R; Lara Primo N
An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California.
Cancer journal (Sudbury, Mass.) 2004;10(5):294-300.
2004: Lara Primo N; Gumerlock Paul H; Mack Philip C; Lau Derick H M; Gandour-Edwards Regina; Edelman Martin J; Albain Kathy S; Law Lisa Y; Longmate Jeff; Frankel Paul; Reddy Gayatri P; Israel Valerie; Doroshow James H; Gandara David R
Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.
Clinical lung cancer 2004;6(2):102-7.
2004: Le Quynh-Thu; McCoy Jason; Williamson Stephen; Ryu Janice; Gaspar Laurie E; Edelman Martin J; Dakhil Shaker R; Sides Stanley D; Crowley John J; Gandara David R;
Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(16):5418-24.
2004: Edelman Martin J; Clark Joseph I; Chansky Kari; Albain Kathy; Bhoopalam Nirmala; Weiss Geoffrey R; Giguere Jeffrey K; Kelly Karen; Crowley John; Gandara David R
Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):5022-6.
2004: Kimura Tatsuo; Holland Will S; Kawaguchi Tomoya; Williamson Stephen K; Chansky Kari; Crowley John J; Doroshow James H; Lenz Heinz-Josef; Gandara David R; Gumerlock Paul H
Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy.
Annals of the New York Academy of Sciences 2004;1022():55-60.
2004: Gandara David R; West Howard; Chansky Kari; Davies Angela M; Lau Derick H M; Crowley John; Gumerlock Paul H; Hirsch Fred R; Franklin Wilbur A
Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 2):4205s-4209s.
2004: Lynch Thomas J; Adjei Alex A; Bunn Paul A; DuBois Raymond N; Gandara David R; Giaccone Giuseppe; Govindan Ramaswamy; Herbst Roy S; Johnson Bruce E; Khuri Fadlo R; Perez-Soler Roman; Rosell Rafael; Rowinsky Eric K; Sandler Alan B; Scagliotti Giorgio V; Schiller Joan H; Shapiro Geoffrey I; Socinski Mark A; Hart Carol S
Novel agents in the treatment of lung cancer: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 2):4199s-4204s.
2004: Chen Allan Y; Chou Rachel; Shih Shyh-Jen; Lau Derick; Gandara David
Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs.
Critical reviews in oncology/hematology 2004;50(2):111-9.
2004: Lara Primo N; Chee Karen Giselle; Longmate Jeff; Ruel Christopher; Meyers Frederick J; Gray Carl R; Edwards Regina Gandour; Gumerlock Paul H; Twardowski Przemyslaw; Doroshow James H; Gandara David R
Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
Cancer 2004;100(10):2125-31.
2004: Davies Angela M; Lara Primo N; Lau Derick H; Gandara David R
Treatment of extensive small cell lung cancer.
Hematology/oncology clinics of North America 2004;18(2):373-85.
2004: Davies Angela M; Mack Philip C; Lara Primo N; Lau Derick H; Danenberg Kathleen; Gumerlock Paul H; Gandara David R
Predictive molecular markers: has the time come for routine use in lung cancer?
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2(2):125-31.
2004: Lara Primo N; Davies Angela M; Mack Philip C; Mortenson Melinda M; Bold Richard J; Gumerlock Paul H; Gandara David R
Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.
Seminars in oncology 2004;31(1 Suppl 1):40-6.
2004: Liu Glenn; Gandara David R; Lara Primo N; Raghavan Derek; Doroshow James H; Twardowski Przemyslaw; Kantoff Philip; Oh William; Kim KyungMann; Wilding George
A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(3):924-8.
2004: Lara Primo N; Laptalo Luko; Longmate Jeff; Lau Derick H M; Gandour-Edwards Regina; Gumerlock Paul H; Doroshow James H; Gandara David R;
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
Clinical lung cancer 2004;5(4):231-6.
2004: Edelman Martin J; Chansky Kari; Gaspar Laurie E; Leigh Bryan; Weiss Geoffrey R; Taylor Sarah A; Crowley John; Livingston Robert; Gandara David R
Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(1):127-32.
2003: Gandara David R
Developing targeted therapies for lung cancer.
Clinical advances in hematology & oncology : H&O 2003;1(11):648-9, 690.
2003: Roberts Peter F; Straznicka Michaela; Lara Primo N; Lau Derrick H; Follette David M; Gandara David R; Benfield John R
Resection of multifocal non-small cell lung cancer when the bronchioloalveolar subtype is involved.
The Journal of thoracic and cardiovascular surgery 2003;126(5):1597-602.
2003: Lara Primo N; Quinn David I; Margolin Kim; Meyers Frederick J; Longmate Jeff; Frankel Paul; Mack Philip C; Turrell Corinne; Valk Peter; Rao Jyotsna; Buckley Penelope; Wun Ted; Gosselin Robert; Galvin Irina; Gumerlock Paul H; Lenz Heinz Josef; Doroshow James H; Gandara David R;
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(13):4772-81.
2003: Lara Primo N; Frankel Paul; Mack Philip C; Gumerlock Paul H; Galvin Irina; Martel Cynthia L; Longmate Jeff; Doroshow James H; Lenz Heinz Josef; Lau Derick H M; Gandara David R
Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(12):4356-62.
2003: Doroshow James H; Synold Timothy W; Gandara David; Mani Sridhar; Remick Scot C; Mulkerin Daniel; Hamilton Anne; Sharma Sunil; Ramanathan Ramesh K; Lenz Heinz Josef; Graham Martin; Longmate Jeffrey; Takimoto Chris H; Ivy Percy
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.
Seminars in oncology 2003;30(4 Suppl 15):14-9.
2003: Mack Philip C; Davies Angela M; Lara Primo N; Gumerlock Paul H; Gandara David R
Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.
Lung cancer (Amsterdam, Netherlands) 2003;41 Suppl 1():S89-96.
2003: Wild Carolyn A; Wang Stephen E; Gandara David R; Lara Primo N; Meyers Frederick J; Tanaka Michael; Houston Joan; Lauder Jun; Lau Derick H
Population-based maximum tolerated dose of irinotecan and carboplatin.
Oncology (Williston Park, N.Y.) 2003;17(7 Suppl 7):11-6.
2003: Gandara David R; Chansky Kari; Albain Kathy S; Leigh Bryan R; Gaspar Laurie E; Lara Primo N; Burris Howard; Gumerlock Paul; Kuebler J Philip; Bearden James D; Crowley John; Livingston Robert;
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10):2004-10.
2003: Mack Philip C; Gandara David R; Lau Alvin H; Lara Primo N; Edelman Martin J; Gumerlock Paul H
Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinoma.
Cancer chemotherapy and pharmacology 2003;51(4):337-48.
2003: Davies Angela M; Lara Primo N; Mack Philip C; Gandara David R
Docetaxel in non-small cell lung cancer: a review.
Expert opinion on pharmacotherapy 2003;4(4):553-65.
2003: Edelman Martin J; Gandara David R; Hausner Petr; Israel Valerie; Thornton Donald; DeSanto Jennifer; Doyle L Austin
Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2003;39(2):197-9.
2003: Davies Angela M; Gandara David R; Lara Primo N; Mack Philip C; Lau Derick H M; Gumerlock Paul H
Antisense oligonucleotides in the treatment of non-small-cell lung cancer.
Clinical lung cancer 2003;4 Suppl 2():S68-73.
2003: Juhasz Agnes; Frankel Paul; Cheng Catherine; Rivera Hector; Vishwanath Reena; Chiu Alice; Margolin Kim; Yen Yun; Newman Edward M; Synold Tim; Wilczynski Sharon; Lenz Heinz-Josef; Gandara David; Albain Kathy S; Longmate Jeffrey; Doroshow James H
Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products.
Journal of clinical laboratory analysis 2003;17(5):184-94.
2003: Lim Nelson; Lara Primo N; Lau Derick H M; Edelman Martin J; Tanaka Michael; al-Jazayrly Ghassan; Houston Joan; Lauder Ignacio; Gandara David R
Phase I trial of gemcitabine and paclitaxel in advanced solid tumors.
Cancer investigation 2003;21(1):7-13.
2003: Perez Edith A; Gandara David R; Edelman Martin J; O'Donnell Robert; Lauder Ignacio J; DeGregorio Michael
Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies.
Cancer investigation 2003;21(1):1-6.
2002: Vokes Everett E; Choy Hak; Gandara David; Mattson Karin
Adjuvant and neoadjuvant treatments for NSCLC.
Lung cancer (Amsterdam, Netherlands) 2002;38 Suppl 4():29-35.
2002: Yen Yun; Chow Warren; Leong Lucille; Margolin Kim; Morgan Robert; Raschko James; Shibata Stephen; Somlo George; Twardowski Przemyslaw; Frankel Paul; Longmate Jeff; Synold Timothy; Newman Edward M; Lenz Heinz-Josef; Gandara David; Doroshow James H
Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial.
Cancer chemotherapy and pharmacology 2002;50(5):353-9.
2002: Albain Kathy S; Crowley John J; Turrisi Andrew T; Gandara David R; Farrar William B; Clark Joseph I; Beasley Kristie R; Livingston Robert B
Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(16):3454-60.
2002: Hesketh Paul J; Nauman Christopher J; Hesketh Ann M; LaPointe Janet; Fogarty Katrina; Oo Thein H; Lau Derick H M; Edelman Martin J; Gandara David R
Unfavorable therapeutic index of cisplatin/gemcitabine/vinorelbine in advanced non-small-cell lung cancer.
Clinical lung cancer 2002;4(1):47-51.
2002: Lord Reginald V N; Brabender Jan; Gandara David; Alberola Vicente; Camps Carlos; Domine Manuel; Cardenal Felip; Sánchez José M; Gumerlock Paul H; Tarón Miquel; Sánchez José J; Danenberg Kathleen D; Danenberg Peter V; Rosell Rafael
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2286-91.
2002: Davies Angela; Gandara David R; Lara Primo; Goldberg Zelanna; Roberts Peter; Lau Derick
Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer.
Seminars in oncology 2002;29(3 Suppl 12):10-6.
2002: Lara Primo N; Goldberg Zelanna; Davies Angela; Lau Derick H M; Gandara David R
Concurrent chemoradiation strategies in the management of unresectable stage III non-small-cell lung cancer.
Clinical lung cancer 2002;3 Suppl 2():S42-8.
2002: Lara Primo N; Meyers Frederick J; Gray Carl R; Edwards Regina Gandour; Gumerlock Paul H; Kauderer Caren; Tichauer Garrett; Twardowski Przemyslaw; Doroshow James H; Gandara David R
HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial.
Cancer 2002;94(10):2584-9.
2002: Moinpour C M; Lyons B; Grevstad P K; Lovato L C; Crowley J; Czaplicki K; Buckner Z M; Ganz P A; Kelly K; Gandara D R
Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2002;11(2):115-26.
2002: Lara Primo N; Lau Derick H M; Gandara David R
Non-small-cell lung cancer progression after first-line chemotherapy.
Current treatment options in oncology 2002;3(1):53-8.
2002: Gandara David R; Lara Primo N; Goldberg Zelanna; Le Quynh T; Mack Phillip C; Lau Derick H M; Gumerlock Paul H
Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia.
Seminars in oncology 2002;29(1 Suppl 4):102-9.
2002: Ramsey Scott D; Moinpour Carol M; Lovato Laura C; Crowley John J; Grevstad Patra; Presant Cary A; Rivkin Saul E; Kelly Karen; Gandara David R
Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
Journal of the National Cancer Institute 2002;94(4):291-7.
2002: Quock Justin; Dea Gilland; Tanaka Michael; Gandara David; Lara Primo; Lau Derick
Premedication strategy for weekly paclitaxel.
Cancer investigation 2002;20(5-6):666-72.
2002: Kuriakose Philip; Gandara David R; Perez Edith A
Phase I trial of edatrexate in advanced breast and other cancers.
Cancer investigation 2002;20(4):473-9.
2001: Gandara D R; Lara P N; Lau D H; Mack P; Gumerlock P H
Molecular-clinical correlative studies in non-small cell lung cancer: application of a three-tiered approach.
Lung cancer (Amsterdam, Netherlands) 2001;34 Suppl 3():S75-80.
2001: Thomas C R; Giroux D J; Janaki L M; Turrisi A T; Crowley J J; Taylor S A; McCracken J D; Shankir Giri P G; Gordon W; Livingston R B; Gandara D R
Ten-year follow-up of Southwest Oncology Group 8269: a phase II trial of concomitant cisplatin-etoposide and daily thoracic radiotherapy in limited small-cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2001;33(2-3):213-9.
2001: Kelly K; Lovato L; Bunn P A; Livingston R B; Zangmeister J; Taylor S A; Roychowdhury D; Crowley J J; Gandara D R;
Cisplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in untreated patients with extensive-stage small cell lung cancer: a phase II trial of the Southwest Oncology Group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2325-9.
2001: Lara P N; Gandara D R; Longmate J; Gumerlock P H; Lau D H; Edelman M J; Gandour-Edwards R; Mack P C; Israel V; Raschko J; Frankel P; Perez E A; Lenz H J; Doroshow J H
Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial.
Cancer chemotherapy and pharmacology 2001;48(1):22-8.
2001: Edelman M J; Gandara D R; Lau D H; Lara P; Lauder I J; Tracy D
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel.
Cancer 2001;92(1):146-52.
2001: Kelly K; Crowley J; Bunn P A; Presant C A; Grevstad P K; Moinpour C M; Ramsey S D; Wozniak A J; Weiss G R; Moore D F; Israel V K; Livingston R B; Gandara D R
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(13):3210-8.
2001: Gandara D R; Lara P N; Goldberg Z; Lau D H
Integration of new chemotherapeutic agents into chemoradiotherapy for stage III non--small cell lung cancer: focus on docetaxel.
Seminars in oncology 2001;28(3 Suppl 9):26-32.
2001: Tetef M L; Synold T W; Chow W; Leong L; Margolin K; Morgan R; Raschko J; Shibata S; Somlo G; Yen Y; Groshen S; Johnson K; Lenz H J; Gandara D; Doroshow J H
Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1569-76.
2001: Lippman S M; Lee J J; Karp D D; Vokes E E; Benner S E; Goodman G E; Khuri F R; Marks R; Winn R J; Fry W; Graziano S L; Gandara D R; Okawara G; Woodhouse C L; Williams B; Perez C; Kim H W; Lotan R; Roth J A; Hong W K
Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer.
Journal of the National Cancer Institute 2001;93(8):605-18.
2001: Gandara D R; Edelman M J; Lara P N; Lau D H
Gemcitabine in combination with new platinum compounds: an update.
Oncology (Williston Park, N.Y.) 2001;15(3 Suppl 6):13-7.
2001: Breathnach O S; Freidlin B; Conley B; Green M R; Johnson D H; Gandara D R; O'Connell M; Shepherd F A; Johnson B E
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1734-42.
2001: Lara P N; Higdon R; Lim N; Kwan K; Tanaka M; Lau D H; Wun T; Welborn J; Meyers F J; Christensen S; O'Donnell R; Richman C; Scudder S A; Tuscano J; Gandara D R; Lam K S
Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1728-33.
2001: Rusch V W; Giroux D J; Kraut M J; Crowley J; Hazuka M; Johnson D; Goldberg M; Detterbeck F; Shepherd F; Burkes R; Winton T; Deschamps C; Livingston R; Gandara D
Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160).
The Journal of thoracic and cardiovascular surgery 2001;121(3):472-83.
2001: Gandara D R; Lara P N; Goldberg Z; Roberts P; Lau D H
Neoadjuvant therapy for non-small cell lung cancer.
Anti-cancer drugs 2001;12 Suppl 1():S5-9.
2001: Lau D; Leigh B; Gandara D; Edelman M; Morgan R; Israel V; Lara P; Wilder R; Ryu J; Doroshow J
Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(2):442-7.
2001: Margolin K; Longmate J; Synold T W; Gandara D R; Weber J; Gonzalez R; Johansen M J; Newman R; Baratta T; Doroshow J H
Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium.
Investigational new drugs 2001;19(4):335-40.
2000: Macdonald J S; Jacobson J L; Modiano M; Moore D F; Gandara D R; Schroder L E; Chapman R A
A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: a Southwest Oncology Group study (SWOG 9413).
Investigational new drugs 2000;18(3):269-73.
2000: Gandara D R; Edelman M; Lara P; Roberts P; Leigh B
Evolution of combined modality therapy for stage III non-small-cell lung cancer.
Oncology (Williston Park, N.Y.) 2000;14(7 Suppl 5):35-41.
2000: Gandara D R; Lau D H; Lara P N; Edelman M J
Gemcitabine/carboplatin combination regimens: importance of dose schedule.
Oncology (Williston Park, N.Y.) 2000;14(7 Suppl 4):26-30.
2000: Fossella F V; DeVore R; Kerr R N; Crawford J; Natale R R; Dunphy F; Kalman L; Miller V; Lee J S; Moore M; Gandara D; Karp D; Vokes E; Kris M; Kim Y; Gamza F; Hammershaimb L
Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(12):2354-62.
2000: Hesketh P J; Roman A; Hesketh A M; Perez E A; Edelman M; Gandara D R
Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2000;8(1):46-8.
2000: Gandara D R; Vokes E; Green M; Bonomi P; Devore R; Comis R; Carbone D; Karp D; Belani C
Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):131-5.
2000: O'Brate A; Tarón M; Gandara D; Rosell R
Sharing new approaches to translational research in non-small cell lung cancer.
The oncologist 2000;5(6):514-9.
1999: Lenz H J; Raghavan D; Doroshow J; Gandara D R
Phase I study of bryostatin-1 in combination with cisplatin in treating patients with metastatic or unresectable solid tumors including non small-cell lung cancer.
Clinical lung cancer 1999;1(2):151-2.
1999: Edelman M J; Gandara D R
Sequential chemotherapy: rationale and clinical trial design in advanced non-small-cell carcinoma.
Clinical lung cancer 1999;1(2):122-7; discussion 128-9.
1999: Gandara D R; Leigh B; Vallieres E; Albain K S
Preoperative chemotherapy in stage III non-small cell lung cancer: long-term outcome.
Lung cancer (Amsterdam, Netherlands) 1999;26(1):3-6.
1999: Mack P C; Gandara D R; Bowen C; Edelman M J; Paglieroni T; Schnier J B; Gelmann E P; Gumerlock P H
RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2596-604.
1999: Murray N; Livingston R B; Shepherd F A; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin J W; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2300-8.
1999: Edelman M J; Gandara D R; Meyers F J; Ishii R; O'Mahony M; Uhrich M; Lauder I; Houston J; Gietzen D W
Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome.
Cancer 1999;86(4):684-8.
1999: Hesketh P J; Crowley J J; Burris H A; Williamson S K; Balcerzak S P; Peereboom D; Goodwin J W; Gross H M; Moore D F; Livingston R B; Gandara D R
Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II trial.
The cancer journal from Scientific American 1999;5(4):237-41.
1999: Leigh B R; Gandara D R; Crowley J J; Furuse K; Livingston R B; Fukushima M; Coltman C A
Summary of the proceedings of the United States--Japan lung cancer clinical trials summit: San Francisco, CA, 20-22 November, 1998.
Lung cancer (Amsterdam, Netherlands) 1999;24(3):181-91.
1999: Gandara D R; Edelman M J; Lau D
Emerging role of docetaxel (Taxotere) in advanced non-small cell lung cancer.
Seminars in oncology 1999;26(3 Suppl 10):3-7.
1999: Lau D; Ryu J; Gandara D; Morgan R; Doroshow J; Wilder R; Leigh B
Concurrent twice-weekly paclitaxel and thoracic irradiation for stage III non-small cell lung cancer.
Seminars in radiation oncology 1999;9(2 Suppl 1):117-20.
1999: Langer C J; Gandara D R; Calvert P; Edelman M J; Ozols R F
Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer.
Seminars in oncology 1999;26(1 Suppl 4):12-8.
1999: Sondak V K; Liu P Y; Flaherty L E; Fletcher W S; Periman P; Gandara D R; Taylor S A; Balcerzak S P; Meyskens F L
A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study.
The cancer journal from Scientific American 1999;5(1):41-7.
1999: Grunberg S M; Crowley J; Hande K R; Giroux D; Munshi N; Lau D H; Schroder L E; Zangmeister M H; Balcerzak S P; Hynes H E; Gandara D R
Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study.
Cancer chemotherapy and pharmacology 1999;44(6):461-8.
1998: Lau D H; Crowley J J; Gandara D R; Hazuka M B; Albain K S; Leigh B; Fletcher W S; Lanier K S; Keiser W L; Livingston R B
Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):3078-81.
1998: Wozniak A J; Crowley J J; Balcerzak S P; Weiss G R; Spiridonidis C H; Baker L H; Albain K S; Kelly K; Taylor S A; Gandara D R; Livingston R B
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(7):2459-65.
1998: Gandara D R; Roila F; Warr D; Edelman M J; Perez E A; Gralla R J
Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy. Dose, schedule, and route of administration.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1998;6(3):237-43.
1998: Edelman M J; Gandara D R
Small cell lung cancer: current status of new chemotherapeutic agents.
Critical reviews in oncology/hematology 1998;27(3):211-20.
1998: Meyskens F L; Jacobson J; Nguyen B; Weiss G R; Gandara D R; MacDonald J S
Phase II trial of oral beta-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157).
Investigational new drugs 1998;16(2):171-3.
1998: Lara P N; Gandara D R; Wurz G T; Lau D; Uhrich M; Turrell C; Raschko J; Edelman M J; Synold T; Doroshow J; Muggia F; Perez E A; DeGregorio M
High-dose toremifene as a cisplatin modulator in metastatic non-small cell lung cancer: targeted plasma levels are achievable clinically.
Cancer chemotherapy and pharmacology 1998;42(6):504-8.
1998: Edelman M J; Gandara D R; Perez E A; Lau D; Lauder I; Turrell C; Uhrich M; Meyers F
Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy.
Investigational new drugs 1998;16(1):69-75.
1997: Lau D H; Ryu J K; Gandara D R
Chemoradiotherapy for poor-risk stage III non-small cell lung cancer.
Seminars in oncology 1997;24(4 Suppl 12):S12-110-S12-112.
1997: Lau D H; Ryu J K; Gandara D R; Morgan R; Doroshow J; Wilder R; Leigh B
Twice-weekly paclitaxel and radiation for stage III non-small cell lung cancer.
Seminars in oncology 1997;24(4 Suppl 12):S12-106-S12-109.
1997: Hesketh P J; Gandara D R; Hesketh A M; Edelman M; Webber L M; McManus M; Hainsworth J D
Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone.
The cancer journal from Scientific American 1997;3(3):180-3.
1997: Lau D H; Ryu J K; Gandara D R; Rosenthal S A
Concurrent carboplatin, etoposide and thoracic radiation for poor-risk stage III non-small-cell lung carcinoma: a pilot study.
International journal of radiation oncology, biology, physics 1997;38(1):157-61.
1997: Hesketh P J; Kris M G; Grunberg S M; Beck T; Hainsworth J D; Harker G; Aapro M S; Gandara D; Lindley C M
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):103-9.
1997: Gandara D R; Edelman M J; Crowley J J; Lau D H; Livingston R B
Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study.
Cancer chemotherapy and pharmacology 1997;41(1):75-8.
1996: Perez E A; Coe T; Turrell C; Lau D; Campbell D; Gandara D
Phase I study of paclitaxel with oral etoposide in advanced solid tumors.
The cancer journal from Scientific American 1996;2(5):286-90.
1996: Edelman M J; Gandara D R; Roach M; Benfield J R
Multimodality therapy in stage III non-small cell lung cancer.
The Annals of thoracic surgery 1996;61(5):1564-72.
1996: Hesketh P J; Gandara D R; Hesketh A M; Facada A; Perez E A; Webber L M; Martin L A; Cramer M B; Hahne W F
Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 1996;4(2):141-6.
1995: Kelly K; Crowley J J; Bunn P A; Hazuka M B; Beasley K; Upchurch C; Weiss G R; Hicks W J; Gandara D R; Rivkin S
Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(12):2924-30.
1995: Kaul S; Igwemezie L N; Stewart D J; Fields S Z; Kosty M; Levithan N; Bukowski R; Gandara D; Goss G; O'Dwyer P
Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(11):2835-41.
1995: Roach M; Gandara D R; Yuo H S; Swift P S; Kroll S; Shrieve D C; Wara W M; Margolis L; Phillips T L
Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(10):2606-12.
1995: Albain K S; Rusch V W; Crowley J J; Rice T W; Turrisi A T; Weick J K; Lonchyna V A; Presant C A; McKenna R J; Gandara D R
Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(8):1880-92.
1995: Bunn P A; Crowley J; Kelly K; Hazuka M B; Beasley K; Upchurch C; Livingston R; Weiss G R; Hicks W J; Gandara D R
Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(7):1632-41.
1995: Navari R; Gandara D; Hesketh P; Hall S; Mailliard J; Ritter H; Friedman C; Fitts D
Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(5):1242-8.
1995: Gandara D R; Nahhas W A; Adelson M D; Lichtman S M; Podczaski E S; Yanovich S; Homesley H D; Braly P; Ritch P S; Weisberg S R
Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(2):490-6.
1994: Mirimanoff R O; Rubin P; Cox J D; Gandara D; Grunenwald D; Hazuka M; Jassem J; Komaki R; Mattson K; McDonald S
Concomitant and alternating radiation therapy (RT) and chemotherapy (CT) for inoperable, M0, non-small cell lung cancers (NSCLC): a consensus report.
Lung cancer (Amsterdam, Netherlands) 1994;11 Suppl 3():S5-8.
1994: Perez E A; Gandara D R
Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer.
Seminars in oncology 1994;21(3 Suppl 4):2-5.
1994: Perez E A; Gandara D R
The clinical role of granisetron (Kytril) in the prevention of chemotherapy-induced emesis.
Seminars in oncology 1994;21(3 Suppl 5):15-21.
1994: Perez E A; Sowray P C; Gardner S L; Gandara D R
Phase I study of high-dose cisplatin, ifosfamide, and etoposide.
Cancer chemotherapy and pharmacology 1994;34(4):331-4.
1993: Albain K S; Crowley J J; Hutchins L; Gandara D; O'Bryan R M; Von Hoff D D; Griffin B; Livingston R B
Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base.
Cancer 1993;72(4):1184-91.
1993: Gandara D R; Crowley J; Livingston R B; Perez E A; Taylor C W; Weiss G; Neefe J R; Hutchins L F; Roach R W; Grunberg S M
Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(5):873-8.
1993: Valone F H; Gandara D R; Luce J A; Wall S; Perez E A; Braham N; George M; Letvak L
Phase I trial of a 5-day infusion of L-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies.
Cancer chemotherapy and pharmacology 1993;32(3):215-20.
1993: Gandara D R; Harvey W H; Monaghan G G; Perez E A; Hesketh P J
Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo.
European journal of cancer (Oxford, England : 1990) 1993;29A Suppl 1():S35-8.
1992: Beck T M; Hesketh P J; Madajewicz S; Navari R M; Pendergrass K; Lester E P; Kish J A; Murphy W K; Hainsworth J D; Gandara D R
Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(12):1969-75.
1992: MacKenzie M R; Wold H; George C; Gandara D; Ray G; Schiff S; Shields J; Artim R; Davidson H; Meyers F
Consolidation hemibody radiotherapy following induction combination chemotherapy in high-tumor-burden multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(11):1769-74.
1992: Perez E A; Gandara D R
Advances in the control of chemotherapy-induced emesis.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3 Suppl 3():47-50.
1992: Gandara D R; Harvey W H; Monaghan G G; Perez E A; Stokes C; Bryson J C; Finn A L; Hesketh P J
The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
Seminars in oncology 1992;19(4 Suppl 10):67-71.
1991: Carlson R W; Sikic B I; Gandara D R; Hendrickson C G; Wittlinger P S; Shields J A; Wong P P; White J E; Meakin C J; McWhirter K M
Late consolidative radiation therapy in the treatment of limited-stage small cell lung cancer.
Cancer 1991;68(5):948-58.
1991: Valone F H; Gandara D R; Deisseroth A B; Perez E A; Rayner A; Aronson F R; Luce J; Paradise C
Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(3):207-13.
1991: Hesketh P J; Gandara D R
Serotonin antagonists: a new class of antiemetic agents.
Journal of the National Cancer Institute 1991;83(9):613-20.
1991: Gandara D R; Valone F H; Perez E A; Deisseroth A B; Roach M; Ahn D K; Phillips T
Rapidly alternating radiotherapy and high dose cisplatin chemotherapy in stage IIIB non-small cell lung cancer: results of a phase I/II study.
International journal of radiation oncology, biology, physics 1991;20(5):1047-52.
1991: Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(5):721-8.
1991: Perez E A; Scudder S A; Meyers F A; Tanaka M S; Paradise C; Gandara D R
Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: a phase I study.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(1):57-62.
1991: Perez E A; Hesketh P J; Gandara D R
Serotonin antagonists in the management of cisplatin-induced emesis.
Seminars in oncology 1991;18(1 Suppl 3):73-80.
1991: Gandara D R; Perez E A; Weibe V; De Gregorio M W
Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity.
Seminars in oncology 1991;18(1 Suppl 3):49-55.
1991: Gandara D R
Progress in the control of acute and delayed emesis induced by cisplatin.
European journal of cancer (Oxford, England : 1990) 1991;27 Suppl 1():S9-11; discussion S22.
1990: Khojasteh A; Sartiano G; Tapazoglou E; Lester E; Gandara D; Bernard S; Finn A
Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study.
Cancer 1990;66(6):1101-5.
1990: Lawrence H J; Gandara D R
Chromosomal abnormalities in non-Hodgkin's lymphoma.
The New England journal of medicine 1990;322(7):475.
1990: Gandara D R; Wiebe V J; Perez E A; Makuch R W; DeGregorio M W
Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate.
Critical reviews in oncology/hematology 1990;10(4):353-65.
1990: Gandara D R; Perez E A; Wold H; Caggiano V; Malec M; Ahn D K; Meyers F; Carlson R W
High-dose cisplatin and mitomycin C in advanced non-small cell lung cancer: a phase II study of the Northern California Oncology Group.
Cancer chemotherapy and pharmacology 1990;27(3):243-7.
1989: Cobos E; Gandara D R; Geier L J; Kirmani S
Post-transfusion purpura and isoimmune neonatal thrombocytopenia in the same family.
American journal of hematology 1989;32(3):235-6.
1989: Gandara D R; Perez E A; Phillips W A; Lawrence H J; DeGregorio M
Evaluation of cisplatin dose intensity: current status and future prospects.
Anticancer research 1989;9(4):1121-8.
1989: Hesketh P J; Murphy W K; Lester E P; Gandara D R; Khojasteh A; Tapazoglou E; Sartiano G P; White D R; Werner K; Chubb J M
GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(6):700-5.
1989: Gandara D R; Wold H; Perez E A; Deisseroth A B; Doroshow J; Meyers F; McWhirter K; Hannigan J; De Gregorio M W
Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen.
Journal of the National Cancer Institute 1989;81(10):790-4.
1989: Gandara D R; Perez E A; Denham A; Wiebe V J; DeGregorio M W
Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens.
Cancer chemotherapy and pharmacology 1989;24(2):135-6.
1989: Lawrence H J; Walsh D; Zapotowski K A; Denham A; Goodnight S H; Gandara D R
Topical dimethylsulfoxide may prevent tissue damage from anthracycline extravasation.
Cancer chemotherapy and pharmacology 1989;23(5):316-8.
1989: DeGregorio M W; Gandara D R; Holleran W M; Perez E A; King C C; Wold H G; Montine T J; Borch R F
High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: preliminary pharmacologic observations.
Cancer chemotherapy and pharmacology 1989;23(5):276-8.
1988: Gandara D R; Perez E A; DeGregorio M W; Borch R
Cisplatin and fluorouracil with or without sodium diethyldithiocarbamate rescue.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(11):1785-7.
1988: Gandara D R; Mackenzie M R
Differential diagnosis of monoclonal gammopathy.
The Medical clinics of North America 1988;72(5):1155-67.
1988: Perez E A; Tanaka M; Gandara D R
Conjugated estrogen for platelet dysfunction associated with liver disease.
The New England journal of medicine 1988;318(23):1543.
1988: Hutchison F N; Perez E A; Gandara D R; Lawrence H J; Kaysen G A
Renal salt wasting in patients treated with cisplatin.
Annals of internal medicine 1988;108(1):21-5.
1987: McLeod B F; Lawrence H J; Smith D W; Vogt P J; Gandara D R
Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency.
Cancer 1987;60(11):2617-20.
1987: Benz C; Gandara D; Miller B; Drakes T; Monroe S; Wilbur B; DeGregorio M
Chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer: endocrine pharmacokinetics and toxicity.
Cancer treatment reports 1987;71(3):283-9.
1987: Gandara D R; George C B; Ries C A; Koretz M M; Lewis J P
Treatment of refractory chronic lymphocytic leukemia with prednimustine: a phase II study using strict response criteria.
Cancer chemotherapy and pharmacology 1987;19(2):165-8.
1987: Valone F H; Kohler M; Fisher K; Hannigan J; Flam M; Gandara D; Hendrickson C; Richman E; Yu K P
A Northern California Oncology Group randomized trial of leucovorin plus 5-fluorouracil versus sequential methotrexate, 5-fluorouracil, and leucovorin in patients with advanced colorectal cancer who failed treatment with 5-fluorouracil or 5-fluorodeoxyuridine alone.
NCI monographs : a publication of the National Cancer Institute 1987;(5):175-7.
1986: Gandara D R; DeGregorio M W; Wold H; Wilbur B J; Kohler M; Lawrence H J; Deisseroth A B; George C B
High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1986;4(12):1787-93.
1986: Gandara D R; Mansour R; Wold H; George C
Dose-limiting myelosuppression associated with high-dose cisplatin (200 mg/m2) in hypertonic saline.
Cancer treatment reports 1986;70(6):820-1.
1986: Gandara D R; Wold H G; Redmond J; Kohler M; Reynolds R; Wong P; Forsythe J; Fisher K; Lewis B
Prednimustine in refractory non-Hodgkin's lymphoma: a phase II study of the Northern California Oncology Group.
Seminars in oncology 1986;13(1 Suppl 1):14-8.
1984: Torti F M; Porzig K J; Gandara D R; Volberding P; Mitchell E; Meyers F J; Kohler M; Gribble M
Phase II trial of 4'-epi-doxorubicin in metastatic melanoma.
Cancer treatment reports 1984;68(12):1509-10.
1984: George C B; Mansour R P; Redmond J; Gandara D R
Hepatic dysfunction and jaundice following high-dose cytosine arabinoside.
Cancer 1984;54(11):2360-2.
1984: Daniels J R; Chak L Y; Sikic B I; Lockbaum P; Kohler M; Carter S K; Reynolds R; Bohnen R; Gandara D; Yu J
Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1984;2(11):1192-9.
1984: Chapman G S; Kumar D; Redmond J; Munderloh S H; Gandara D R
Upper abdominal computerized tomography scanning in staging non-small cell lung carcinoma.
Cancer 1984;54(8):1541-3.
1984: Swift J F; Wold H G; Gandara D R; Redmond J; George C B
Prolymphocytic leukemia. Serial responses to therapy.
Cancer 1984;54(6):978-80.
1984: Volk S A; Mansour R F; Gandara D R; Redmond J
Morbidity in long-term survivors of small cell carcinoma of the lung.
Cancer 1984;54(1):25-7.
1983: Redmond J; Stites D P; Beckstead J H; George C B; Casavant C H; Gandara D R
Chronic lymphocytic leukemia with osteolytic bone lesions, hypercalcemia, and monoclonal protein.
American journal of clinical pathology 1983;79(5):616-20.
1982: Chapman G S; Kumar D; Redmond J; Gandara D R
Upper abdominal CT scanning in staging non-oat-cell lung carcinoma.
The New England journal of medicine 1982;307(3):189.
1982: Gandara D R; Ries C A; Schiff S A; George C B; Lewis J P; Koretz M M; Carter S K
A phase II study of prednimustine in acute non-lymphocytic leukemia, smouldering leukemia, and refractory anemia with excess blasts.
Cancer chemotherapy and pharmacology 1982;9(1):10-2.
1979: Gandara D R; Fariss B L
Persistence of periodic paralysis following treatment of thyrotoxicosis: case report.
Military medicine 1979;144(5):337-8.
1978: Schlesinger J J; Gandara D; Bensch K G
Myoglobinuria associated with herpes-group viral infections.
Archives of internal medicine 1978;138(3):422-4.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

David Gandara

Research Profile (preview)

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of David Gandara (preview)

All Publications